Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis

In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Products (Pty) Ltd would like to inform you of the risk of Severe Cutaneous Adverse Reactions (SCARs) and immune-related myositis associated with the use of Tecentriq® (azeolizumab).

2020 Nov

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance